Клинико-функциональное состояние печени у женщин с артериальной гипертензией и менопаузальным метаболическим синдромом в ходе антигипертензивной терапии
Сметанин Михаил Юрьевич, Л. Т. Пименов · Курский научно-практический вестник "Человек и его здоровье" · 2008
We investigated the 12-week monotherapeutic influence of Rilmenidine, Metoprolol and Hydrochlorothiazide on the clinical and dynamic liver condition in 110 women having mild-to-moderate arterial hypertension and menopausal metabolic syndrome. 37 patients took the 1-2 mg/day dose of Rilmenidine, 36 the 50-100 mg/day dose of Metoprolol, 37 12.5-25 mg/day dose of Hydrochlorothiazide. To evaluate the clinical and dynamic liver condition we obtained the case history, examined the patients and analyzed the activity of hepatic enzymes, the content of total bilirubin, total protein and albumin, cholesterol and its fractions, triglycerides, glucose (along with oral glucose load), C-peptide, immunoreactive insulin (along with insulin resistance index assessment); the patients had hepatic sonography made. The results of investigation showed that Rilmenidine, Metoprolol and Hydrochlorothiazide therapy did not make worse any signs of the dynamic liver condition in the patients suffering from mild-to-moderate arterial hypertension and menopausal metabolic syndrome. More than half the patients were revealed fatty hepatosis (steatosis) according to the results of hepatic sonography only.
Cited by 0 works.